Ongoing
Closed
MICROBIOTA-ESG STUDY. ASSESSMENT OF THE COMPOSITION OF THE INTESTINAL MICROBIOTA AND THE PREVALENCE AND SEVERITY OF IBS-LIKE SYMPTOMS PRE- AND POST ENDOSCOPIC VERTICAL GASTROPLASTIC SURGERY
Wed Feb 1, 2023
Study of the role of environmental factors in the etiopathogenesis of dysbiosis associated with Chronic Gastrointestinal Disorders
Sun Jan 1, 2023
Evaluation of the impact of the intake of products with a high amylose content on the symptoms and modulation of the intestinal microbiota of patients suffering from Irritable Bowel Syndrome (IBS)
Tue 1 Sept, 2020
Evaluation of the effect of the integrin-receptor antagonist Vedolizumab (VDZ) on intestinal barrier integrity and microbiota composition in patients with Inflammatory Bowel Disease
Thu Mar 1, 2018
A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel syndrome
Sun Jan 1, 2017
L. CASEI DG® (LACTOBACILLUS PARACASEI CNCMI1572; ENTEROLACTIS®PLUS) IN THE TREATMENT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLELGROUP, PLACEBO CONTROLLED STUDY
Sun Jan 1, 2017
Evaluation of symptoms prevalence related to Dumping Syndrome (DS), reactive ipoglycemia and glycemia variability in patients with gastric cancer undergoing to total or partial gastrectomy
Sun Jan 1, 2017
